BC Tyrosine Kinase Inhibitors Registry and Biorepository, Canada

Registration Status: Completed

Objective: Leukemia and Lymphoma are one of the most common cancers found in children and adults. Chemotherapy remains the mainstay treatment option for Leukemia and Lymphoma cancers and the specific use of tyrosine kinase inhibitors have recently revolutionized the treatment for chronic myeloid leukemia and B cell lymphoma malignancies. While this class of chemotherapy agents drastically reduced the rates of mortality and improved survival outcomes, they are thought to be significantly cardiotoxic and predisposes individuals to cardiac co-morbidities later in life. Little remains known about the risk factors associated with tyrosine kinase inhibitors induced cardiotoxicity, and consequently there are no risk-based guidelines that provide treatment protocols for children or adults receiving this therapy. Thus, the overarching goal of this study is to establish a combined clinical registry and genetic biorepository from patients exposed to tyrosine kinase inhibitors to better assess and predict individuals at risk for developing cardiotoxicity.

Registered Biobank Name BC Tyrosine Kinase Inhibitors Registry and Biorepository
Biobank Leader Brandon Chalazan
Country Canada
Email for biobank inquiries brandon.chalazan@cw.bc.ca
Principal Investigator Brandon Chalazan
Website
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected:
Cohort Highlights